We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Smithfield Bioscience Draws Form 483 Over Repeat Batch Discrepancies
Smithfield Bioscience Draws Form 483 Over Repeat Batch Discrepancies
The FDA hit Smithfield Bioscience with a Form 483 over unexplained batch discrepancies for its blood thinner heparin — a repeat observation from 2019 — following a July 2022 inspection of the company’s Cincinnati, Ohio, facility.
